Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 11
2003 12
2004 10
2005 7
2006 7
2007 9
2008 6
2009 13
2010 9
2011 7
2012 12
2013 5
2014 11
2015 12
2016 11
2017 7
2018 15
2019 11
2020 16
2021 14
2022 10
2023 8
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Results by year

Filters applied: . Clear all
Page 1
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC. Gulla A, et al. Among authors: tai yt. Blood Cancer Discov. 2021 Sep;2(5):468-483. doi: 10.1158/2643-3230.BCD-21-0047. Epub 2021 Apr 23. Blood Cancer Discov. 2021. PMID: 34568832 Free PMC article.
BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.
Kurata K, Samur MK, Liow P, Wen K, Yamamoto L, Liu J, Morelli E, Gulla A, Tai YT, Qi J, Hideshima T, Anderson KC. Kurata K, et al. Among authors: tai yt. Clin Cancer Res. 2023 May 1;29(9):1807-1821. doi: 10.1158/1078-0432.CCR-22-3668. Clin Cancer Res. 2023. PMID: 36780189 Free PMC article.
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti M, Munshi NC, Wu H, Carrasco RD, Chauhan D, Anderson KC. Du T, et al. Among authors: tai yt. Blood. 2023 May 25;141(21):2599-2614. doi: 10.1182/blood.2022017897. Blood. 2023. PMID: 36630605
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. de Weers M, et al. Among authors: tai yt. J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27. J Immunol. 2011. PMID: 21187443 Clinical Trial.
Targeting CD38 alleviates tumor-induced immunosuppression.
Tai YT, Anderson KC. Tai YT, et al. Oncotarget. 2017 Dec 26;8(68):112166-112167. doi: 10.18632/oncotarget.22992. eCollection 2017 Dec 22. Oncotarget. 2017. PMID: 29348814 Free PMC article. No abstract available.
Daratumumab granted breakthrough drug status.
Laubach JP, Tai YT, Richardson PG, Anderson KC. Laubach JP, et al. Among authors: tai yt. Expert Opin Investig Drugs. 2014 Apr;23(4):445-52. doi: 10.1517/13543784.2014.889681. Epub 2014 Feb 20. Expert Opin Investig Drugs. 2014. PMID: 24555809
209 results